Last updated: April 16, 2026
Case Overview
Hospira Inc. filed a patent infringement lawsuit against Aurobindo Pharma Ltd. in the United States District Court for the District of Delaware on February 25, 2014. The case concerns generic pharmaceutical products allegedly infringing on patents held by Hospira related to a sterile injectable drug.
Filing Details
- Court: District of Delaware
- Docket Number: 1:14-cv-00486
- Filing Date: February 25, 2014
- Parties:
- Plaintiff: Hospira Inc.
- Defendant: Aurobindo Pharma Ltd.
Patent(s) in Dispute
The lawsuit references several patents related to the manufacturing and formulation of a specific sterile injectable. The main patent listed is U.S. Patent No. 8,748,582, which covers a pharmaceutical composition with particular stability and bioavailability properties.
Allegations
Hospira alleges that Aurobindo's generic versions of the drug infringe on its patents. The complaint prioritizes claims of patent infringement related to the composition and manufacturing process, asserting that Aurobindo's products violate valid patent rights.
Legal Proceedings and Developments
Initial Pleadings
Hospira filed the complaint seeking injunctive relief, damages, and attorney fees. Aurobindo responded with a request to dismiss, asserting that the patents are invalid or not infringed.
Patent Challenge
During the case, Aurobindo challenged the validity of the patents through inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB), citing prior art references that questioned patent novelty and obviousness.
Settlement and Dissolution
The case was settled in 2016, with Aurobindo agreeing to certain restrictions on its product line and licensing arrangements. Specific settlement terms remain confidential.
Key Judicial Decisions
- Preliminary Injunction Denial: The court denied Hospira's motion for a preliminary injunction, citing insufficient evidence of irreparable harm and likelihood of success on the patent validity.
- Summary Judgment: In 2016, the court granted summary judgment that certain patents were invalid, but others remained enforceable, leading to a partial victory for Hospira.
Patent Status Post-Litigation
Several patents involved in the litigation were declared invalid or expired by 2018, eroding Hospira’s patent protections. The Aurobindo generic products received FDA approval to market the drugs, subject to the settlement restrictions.
Industry Impact
This case highlighted the growing use of IPR proceedings as a tool for challenging patent validity in pharmaceutical litigation. It also exemplifies the strategic interplay between district court litigation and PTAB proceedings.
Analysis
Patent Strength and Vulnerability
Hospira’s patents were challenged effectively during IPR, leading to their partial invalidation. The court's rulings suggest vulnerabilities that generic competitors can exploit, especially where patents face prior art challenges.
Strategic Litigation Considerations
Hospira pursued both district court and PTAB proceedings simultaneously. The outcome underscores the importance of early patent analysis and proactive defenses, as well as the risks associated with patent robustness.
Settlement Implications
The settlement limited the scope of Aurobindo's market entry but did not resolve all patent rights, leaving open the possibility of future patent challenges or litigations on different formulations.
Key Takeaways
- Patent validity can be compromised through IPR proceedings, impacting enforcement strategies.
- Settlements in pharmaceutical patent disputes can involve licensing arrangements that influence market competition.
- Courts may deny preliminary injunctions if irreparable harm or success on the merits is not sufficiently demonstrated.
- Patent portfolios should be regularly reviewed for vulnerabilities in light of prior art and procedural challenges.
- Industry shifts toward IPR use as a defense mechanism underscore the importance of robust patent drafting.
FAQs
1. Why did Hospira lose some of its patents in this case?
Aurobindo challenged the patents through PTAB IPR proceedings, citing prior art that invalidated claims. The court later granted summary judgment that some patents were invalid.
2. How did the settlement affect market competition?
The settlement limited Aurobindo’s ability to produce certain formulations temporarily, delaying generic entry and maintaining some of Hospira’s market exclusivity.
3. What role did IPR proceedings play in this litigation?
IPR proceedings provided a platform to challenge patent validity, which ultimately led to the invalidation of some patents, influencing the litigation outcome.
4. Are patent invalidations common in pharmaceutical patent disputes?
Yes. IPRs have become a key strategy for challengers to weaken patent protections, especially when facing weak or overly broad patents.
5. How can patent owners protect their rights against challenges?
By drafting strong, narrow claims, conducting thorough prior art searches before filing, and actively defending against early challenges through legal and procedural strategies.
References
[1] U.S. District Court, District of Delaware. (2014). Case No. 1:14-cv-00486. Litigations and filings.
